By Scott Gottlieb (original source Health Affairs)
“In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies. Enhanced funding through user fees and the bipartisan Twenty-First Century Cures legislation have supported a robust and better-resourced FDA and enabled science-driven collaborations in a range of areas including innovative clinical trials, “patient-focused” drug development, and greater clarity around standards for regulatory approval of new technologies.”
Click here to read more
Dr. Sanjay Gupta: How Replaceable Is the Human Body?
For centuries, humans have tried to repair and replace our body parts — from brass noses and pig organs to today’s lab-grown tissue. So where do we stand now? Sanjay sits down with…
Thought Leader: Sanjay Gupta
Peter Zeihan: Venezuela’s End: Was a Deal Struck?
There’s been speculation that a deal could have been struck between the US and a power like Russia or China that allowed the US to…
Thought Leader: Peter Zeihan
Niall Ferguson: The U.S. Should Finish the Job in Iran
Iran is in crisis. The largest protests in years have brought millions into the streets, and sparked a brutal crackdown by the regime. More than…
Thought Leader: Niall Ferguson
Dr. Scott Gottlieb on Finding Cures for Rare Diseases
Thought Leader: Scott Gottlieb
Dr. Scott Gottlieb: What’s Next for Childhood Vaccines
Thought Leader: Scott Gottlieb
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
